Premium
Emnar Pharma Pvt. Ltd (formerly Emmennar Pharma), a part of the Virchow group, is likely to see a rebound in profitability for the fiscal year ended March 2024, owing to declining debt levels and raw material costs. The Hyderabad-headquartered pharmaceutical company, which specializes in API, biotech and drug intermediaries, recorded a ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.